RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
          펼치기
        • 주제분류
        • 발행연도
          펼치기
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • Furosemide가 생쥐 신장의 Alkaline Phosphatase와 Lactate Dehydrogenase의 활성에 미치는 영향

        최성협,최희석 인제대학교 1987 仁濟醫學 Vol.8 No.2

        Furosemide가 생쥐 신장의 재흡수에 관여하는 alkaline phosphatase와 glucose 신생합성이나 초기 병리학적인 소견을 지시하는 세포질내 효소인 lactate dehydrogenase 활성에 미치는 영향을 조직 화학적으로 효소의 소재에 따른 변화를 규명하고자 하였다. Alkaline phosphatase 활성은 주로 근위세뇨관 상피 세포의 쇄자연에서 일어나 투여 4시간군에서 부터 저하되기 시작했으며 latctate dehydrogenase 활성변화는 근위세뇨관의 상피 세포질내에서 일어나 투여 12시간군부터 저하되기 시작했다. This experiment was carried out to investigate the effect of furosemide upon renal enzymes in the mous. Furosemide 0.1 mg was injected intraperitoneally twice a day for four days. Histochemical studies were observed on the activities of alkaline phosphatase and lactate dehydrogellase in mouse kidney. The following results were obtained: 1.The activity of alkaline phosphatase befall to decrease from th 4 hour group in the brush border of the proximal tubules. 2.The activity of lactate dehydrogenase began to decrease from the 12 hour group in the proximal tubules.

      • KCI등재

        Effects of α-Lipoic Acid on the Antioxidant System in Prostate Cancer Cells

        최성협,민권식,최익준,강동일 대한비뇨의학회 2009 Investigative and Clinical Urology Vol.50 No.1

        Purpose: Overproduction of lipid peroxidation byproducts and disturbances in the antioxidant defense system have been implicated in the pathogenesis of several diseases, including prostate cancer. Although several studies have investigated the level of lipid peroxidation and antioxidants in prostate cancer, there are no reports on α-lipoic acid(ALA) in prostate cancer. Here we assessed the effects of ALA on the antioxidant system in prostate cancer cells. Materials and Methods: PC-3, LNCaP, and RWPE-2 cell lines were used in this study. Redox factor(Ref)-1 protein was measured by Western blot analysis after treatment with ALA. Real-time polymerase chain reaction (RT-PCR) was performed to detect superoxide dismutase(SOD)-1 and -2, catalase, and glutathione peroxidase(GSH-Px) mRNA expression. Results: Ref-1 was expressed in the PC-3, LNCaP, and RWPE-2 cell lines. The expression of Ref-1 protein was increased after treatment with 125, 250, and 500μM ALA in the PC-3(p<0.05) and LNCaP(p>0.05) cells compared with the RWPE-2 cells at 48 hours. In PC-3 cells, the mRNA expression of SOD-1, SOD-2, catalase, and GSH-Px decreased at 24 and 48 hours dose-dependently compared with that in RWPE-2 cells(p<0.05). The mRNA expression of SOD-2, catalase, and GSH-Px in LNCaP cell decreased at 48 hours dose-dependently(p<0.05). Conclusions: The expression of Ref-1 protein and antioxidant enzymes changed after ALA exposure in prostate cancer cells. Our findings suggest that ALA affects the antioxidant system in prostate cancer cells and may be related to compensatory changes in the antioxidant defense system of the cells. Purpose: Overproduction of lipid peroxidation byproducts and disturbances in the antioxidant defense system have been implicated in the pathogenesis of several diseases, including prostate cancer. Although several studies have investigated the level of lipid peroxidation and antioxidants in prostate cancer, there are no reports on α-lipoic acid(ALA) in prostate cancer. Here we assessed the effects of ALA on the antioxidant system in prostate cancer cells. Materials and Methods: PC-3, LNCaP, and RWPE-2 cell lines were used in this study. Redox factor(Ref)-1 protein was measured by Western blot analysis after treatment with ALA. Real-time polymerase chain reaction (RT-PCR) was performed to detect superoxide dismutase(SOD)-1 and -2, catalase, and glutathione peroxidase(GSH-Px) mRNA expression. Results: Ref-1 was expressed in the PC-3, LNCaP, and RWPE-2 cell lines. The expression of Ref-1 protein was increased after treatment with 125, 250, and 500μM ALA in the PC-3(p<0.05) and LNCaP(p>0.05) cells compared with the RWPE-2 cells at 48 hours. In PC-3 cells, the mRNA expression of SOD-1, SOD-2, catalase, and GSH-Px decreased at 24 and 48 hours dose-dependently compared with that in RWPE-2 cells(p<0.05). The mRNA expression of SOD-2, catalase, and GSH-Px in LNCaP cell decreased at 48 hours dose-dependently(p<0.05). Conclusions: The expression of Ref-1 protein and antioxidant enzymes changed after ALA exposure in prostate cancer cells. Our findings suggest that ALA affects the antioxidant system in prostate cancer cells and may be related to compensatory changes in the antioxidant defense system of the cells.

      • 전립선암에서 p53 및 PSA 발현에 관한 연구

        최성협 인제대학교 1999 仁濟醫學 Vol.20 No.1S

        전립선 암종은 낮은 병기에서는 추가 수술이나 방사선 또는 홀몬 요법 등 보조적 치료가 필요없다고 알려져 있으나 근래에 저침윤성 병기라 할지라도 비교적 긴 기간 추적 소사를 하면 전이나 재발을 하는 비율이 낮지 않다는 보고들이 나타나고 있다. 따라서 저침윤성 병기의 전립선 암종에서 보조적 치료가 필요한지 여부를 일차 수술후에라도 알 수 있다면 전립선 환자의 치료에 큰 도움을 줄 수 있을 것이다. 본 연구는 이와 같은 견지에서 임상적 병기 및 조직학적 분화도에 따라 p53의 과잉 발현 및 prostatic specific antigen(PSA)의 발현 등으로 그 예후를 알 수 있는가를 알아보기 위해 시도되었다. 본 연구의 성적을 요약하면 p53의 과잉 발현은 조직 분화도가 나쁠수록 또한 병기가 높을수록 강한 양성을 보였으나 통계학적 유의성은 없었으며, 한 종양 조직에서도 조직의 분화도가 나쁜 부위에서 양성률이 더 높은 경향을 나타내었다. 조직내에서 PSA의 발현은 조직 분화도가 높은 편이 양성률이 높았고 혈청내 PSA 치와는 상관관계를 인정할 수 없었다. 따라서 p53은 예후 측정 인자로서는 유의할 수 있어도 수술후 보조적 요법을 행할 것인가 여부를 결정하는데는 큰 도움을 줄 수 없을 것으로 생각된다. The great majority of Stage A prostatic carcinoma was known to be latent in the true sense or had a low biologic potential and hence required no additional therapy, such as radiation or hormone therapy. Recently nontreatment of Stage A carcinoma has been challenged, because they have developed progression of their disease when followed for a long time. But aggressive treatment of all patients with Stage A prostatic carcinoma would result in unnecessary additional treatment in many cases. Thus development of a method to investigate the necessity for additional treatment after first surgery would be a great help for prostatic cancer management. This study is carried out to determine the usefulness of immunohistochemical demonstration of p53 and prostatic specific antigen (PSA) as a prognostic factor. These parameters were compared with well known prognostic factors, such as clinical stages, histologic differentiation and bone metastasis in the 45 cases of transurethrally resected prostatic carcinoma. The results were summarized as follow : p53 was expressed higher percentage and degree in poorly differentiated tumors than well differentiated tumor and in Stage D than lower stage tumors. PSA expression showed higher percentage and degree in well differentiated turners and in stage A tumors. The results suggested that the expression of p53 and PSA could be used as a useful prognostic factors in the prostatic carcinoma.

      • KCI등재SCOPUS
      • 양성 전립선대비증에 대한α1-차단제 단독요법 및 5α-환원효소억제제 병합요법의 효과

        최성협 인제대학교 1999 仁濟醫學 Vol.20 No.1

        전립선비대증의 약물 치료로서 주로 α1-차단제와 5α-환원효소 억제제가 사용된다. α1-차단제는 방광 경부와 후부요도의 평활근을 이완시켜 기능적 배뇨를 촉진시키고, 5α-환원효소억제제는 디하이드로테스토스테론 생성을 억제함으로서 전립선 성장을 억제하고 크기를 감소시킨다. α1-차단제 단독투여시의 효과와 5α-환원 효소 억제제를 병용했을 때의 효과를 비교 분석하고자 하였다. 연구 결과 두 가지 방법이 전립선비대증에 의한 배뇨곤란을 현저하게 호전시켰으며, 두 군간의 유의한 차이는 없었으나 5α-환원효소 억제제 투여군에서 전립선 용적이 장기적으로 감소되는 양상을 보였다. Object: This studdy was made to compare the efficacy of doxazocin(α1-blocker) and doxazocin/finasteride (5α-reductase inhibitor) in the treatment of benign prostatic hyperplasia. Method : From February 1996 to November 1998, 31 patients were treated with 2-4mg/day of doxazocin for 6 months. 42 patients were treated with 2-4mg/day of doxazocin and 5mg/day of finasteride for over 12 months. Assessment parameters were International Prostatic Symptom Score(I-PSS), uroflowmetry and transrectal ultrasonography. Results : At 6months, obstructive symptom score and irritative symptom score were improved from 10.3, 6.5 to 5.9, 3.9 respectively in doxazocin group. The scores were improved from 11.4, 6.8 to 6.3, 4.1 respectively in combination group. In doxazocin group (n = 19), the maximal flow rates were inlproved from 9.1ml/sec to 14.2ml/sec(52.9%), and the average flow rates were improved from 5.4ml/sec to 7.5ml/sec (41.3%) after 6 months of treatment. In combination group(n= 24), the maximal flow rates were improved from 10.4ml/sec to 14.7ml/sec(41.3%), and the average flow rates were improved from 4.9ml/sec to 6.7ml/sec(36.7%) after 6 months of treatment. There was no significant statistical difference between α1-b1ocker monotherapy and combination therapy. The volume reduction of the prostate after 6 and 12 months of finasteride group were 18.5% and 26.9%. Conclusion : α1-blocker and combination therapy improve the symptoms and flow rates of benign prostatic hyperplasia. There was no significant difference between α1-blocker monotherapy and combination therapy with 5α-reductaee inhibitor. 5α-reductase inhibitor showed significant reduction of the prostate volume after 12 months of treatment.

      • 발기부전 환자의 감별 진단에 대한 Rigiscan^ⓡ 검사의 의의

        강상재,최성협 인제대학교 1990 仁濟醫學 Vol.11 No.2

        성기능장애를 진단하는데 있어서 종래의 진단법들과는 달리 야간 음경발기와 강직도를 동시에 측정할 수 있는 RigiscanR을 이용하여 임상적 응용의 효율성을 살펴 보았다. We studied 30 male patients complaining of impotence. Underlying causes were psycogenic (12 paients) and injuries (18 patients). Rigiscan is preferred than other diagnostic tools of impotence to differentiate psycogenic from organic impotence due to continuous and simultaneous recording of nocturnal penile rigidity and tumescence. The results obtained were as follows : 1.In 21 patients shown normal rigiscan, the number of erection was 1.86±0.91 times per night, duration was 12.39±6.41 minutes at tip and 17.03±8.95 minutes at base, tumescence change was 2.86±0.73cm at tip and 2.90±0.68cm at base, rigidity was 66.90±17.08% at tip and 87.85±13.31% at base. 2.In 9 patients shown abnormal rigiscan, the number of erection was 0 per night, duration was 0.92±1.64 minutes at tip and 2.43±3.59 minutes at base. tumescence change was 1.46±0.78cm at tip and 1.69±0.79cm at base, rigidity was 8.26±15.64% at tip and 24.68±30.21% at base. 3.Normal rigiscan showed in 21 patients (11 of psychogenic, 10 of injured patient) but quality of normal event, duration and rigidity were poor.

      • KCI등재SCOPUS
      • KCI등재SCOPUS
      • 표재성 방광암에서 Adriamycin, Mitomycin C 및 BCG의 예방 효과에 대한 비교

        정재일,최성협 인제대학교 1996 仁濟醫學 Vol.17 No.1

        표재성 방광암의 경요도 절제술 후 재발방지를 위해 사용하는 방광내 약물주입요법 중 Advidamycin, Mitomycin C 및 BCG의 약효를 비교하여 가장 효과적인 약물이 무엇인지 알고자 하였다. We tried to compare the prophylactic effect of intravesical administration of Adriamycin(ADR), Mitomycin-C(MMC), and BCG at superficial bladder tumor. Sixty two patients with biopsy-confirmed transitional cell carcinoma of the bladder were studded in a cooperative protocol comparing intravesical Adriamycin, Mitomycin C and BCG. Patients have been followed for 6-72months(median 26.4months) at 3-month intervals with cystoscopy, urine cytology and bladder biopsy if recurrence was suspected. Five of eighteen(27.8% ) who received BCG immunotherapy, eleven of twenty five(44%) who received Adriamycin chem-otherapy, seven of nineteen(36.7% ) who received Mitomycin C developed tumor recurrence. Among three groups, median recurrent period and progression rate were not significantly differente statistically(P>0.05). Adverse reaction of three groups was only symptomatic cystitis and occurrence rates of BCG, Mitomycin C and Adriamycin were 5/18(27.8%), 6/19(31.6% ) and 13/25(52%). These data suggest that BCG immunotherapy is superior to Adriamycin chemotherapy in prevention of recurrent superficial transitional cell carcinoma of the urinary bladder and less side effect(P<0.05) but no significant difference was found between BCG and Mitomycin C.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼